The Methodist Hospital Research Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, The Methodist Hospital Research Institute sits in the top decile of US sponsors by registered trial count (#214 of 15,742 sponsors by registered trial count).
The Methodist Hospital Research Institute: 126 sponsored US clinical trials, 49 recruiting.
The Methodist Hospital Research Institute sponsors 126 registered US clinical trials on ClinicalTrials.gov, 49 of them currently recruiting, and 48 completed. 12 of these trials are in Phase 3-4 (later-stage) and 65 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Urge Incontinence, with 2 trials.
Top-decile sponsor footprint
The Methodist Hospital Research Institute ranks in the top decile of sponsors by registered trial count (#214 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
48 of 64 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
126 total, page 2 of 3
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
NCT05241340
Study in ALS With Abatacept & IL-2
NCT06307301
Neoadjuvant Atezolizumab in Cutaneous Melanoma
NCT04020809
Durvalumab with Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
NCT03820141
ORIF Distal Radius Blood Flow Restriction Therapy
NCT06136286
T-regulatory Cells in ALS
NCT04055623
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
NCT03742245
Phase Ib of L-NMMA and Pembrolizumab
NCT03236935
Mesenchymal Stromal Cells in Living Donor Kidney Transplantation
NCT03478215
IO Vancomycin Spine
NCT06748144
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
NCT07060001
NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers
NCT07060014
Knee Isometric Program (KIP) Home Exercise Programs (HEP) Physical Therapy (PT) Study
NCT06536426
Low-intensity Shockwave Therapy for Post-radical Prostatectomy Erectile Dysfunction
NCT06219785
Feasibility and Acceptability of ReCognitionVR-based Cognitive Stimulation in Surgical Patients
NCT06232317
Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction
NCT06059066
Survey of Human Rabies Immune Globulin Safety in Children
NCT05382650
Ultrasound Evaluation for Baxter VASCU-GUARD Vascular Patches Post-Endarterectomy and Complications Assessment
NCT07048067
Neuromuscular Training in Female Youth Soccer
NCT06136299
Usability, Acceptability, and Safety of Virtual Reality-based Cognitive Intervention
NCT05583903
Procedural Discomfort Related to Number of Intradetrusor Botox Injections
NCT05652036
Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy
NCT04911166
Low-Dose Lidocaine Infusion for Acute Pain Management Pilot Study
NCT06725485
Opioid Use After Thyroid and Parathyroid Surgeries
NCT04955444
Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer
NCT04095689
Mapping of the Human Brainstem During Continence and Micturition: Noninvasive 7-T fMRI Study
NCT04846387
68 Ga-PSMA for High Risk Prostate Cancer
NCT04614363
Educating Women About Pelvic Floor Disorders During Pregnancy
NCT05440539
Sleep & Stress in Healthcare Providers After Defined Music Intervention Measure by 7-Tesla fMRI & Actigraphy
NCT05980429
Intraosseous Morphine in Primary TKA
NCT04388111
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)
NCT04554992
Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol
NCT04042233
Improving Adherence to Rabies PEP Guideline Recommendations
NCT04213950
Motion Capture: Baseball Swing
NCT04503070
7T MRI to Evaluate Cartilage Defects in the Knee
NCT04118023
Trial to Study Electro-Acupuncture in Subjects With Chemotherapy-Induced Peripheral Neuropathy
NCT07455409
Low Dose IL2 Immunotherapy in AD
NCT05821153
Brain Imaging in Men With Lower Urinary Tract Symptoms
NCT03991429
Explore Transplant @Home Within Kaiser Permanente Southern California
NCT03389932
Brain Targets in Patients With Bladder Emptying Difficulties
NCT03574610
Heart Failure Hospital Readmissions and Physical Therapy
NCT03517514
Blood Flow Restriction Training for The Shoulder
NCT04540367
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
NCT03004183
TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
NCT02988986
Deep Brain Stimulation in Patients With LUTS
NCT03202251
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
NCT02834403
Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis
NCT03241784
Explore Transplant at Home: Improving Low-Income ESRD Patients' Transplant Knowledge
NCT02268682
Your Path to Transplant: A Randomized Control Trial of A Tailored Computer Education Intervention for Living Donor Kidney Transplant
NCT02181114
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
NCT02176720
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 30 |
| Phase 2 | 35 |
| Phase 3 | 2 |
| Phase 4 | 10 |
What is open in the The Methodist Hospital Research Institute pipeline
49 recruiting of 126 indexed (39% open); 48 completed (38%).
Phase mix: 12 late (III/IV) vs 65 early (I/II) (early-phase heavy).
Top condition: Urge Incontinence (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
The Methodist Hospital Research Institute: open-pipeline peers nationwide
Peers matched on 126 registered trials and 39% open enrollment, not the therapeutic-area sidebar.
The Methodist Hospital Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 126 trials (± recruiting share)
- Stony Brook University · 127 trials · 19% recruiting
- Methodist Health System · 125 trials · 29% recruiting
- Jazz Pharmaceuticals · 128 trials · 12% recruiting
- University of Illinois at Urbana-Champaign · 129 trials · 14% recruiting
Sponsors near 39% open enrollment (± trial volume)
- argenx · 39% recruiting · 49 trials
- Morehouse School of Medicine · 38% recruiting · 13 trials
- Northeastern University · 38% recruiting · 39 trials
- Thomas Hope · 38% recruiting · 13 trials
Related
What to do with this The Methodist Hospital Research Institute page
126 registered trials is a research-attention snapshot, not an endorsement of The Methodist Hospital Research Institute or any single study.
- 49 of The Methodist Hospital Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Urge Incontinence is the condition The Methodist Hospital Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Urge Incontinence trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
The Methodist Hospital Research Institute pipeline card: 126 registered trials from official public datasets.Report a data error.